MethylDetect

MethylDetect

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MethylDetect ApS is a Copenhagen-based provider of epigenetic research tools, specializing in DNA methylation analysis. The company's core product line, EpiMelt, includes ready-to-use methylation detection assays, a real-time PCR master mix, and bisulfite modification kits, all centered on making MS-HRM technology accessible. Targeting academic and industrial researchers, MethylDetect operates in the growing field of epigenetic diagnostics, with applications spanning cancer, neurological disorders, and other complex diseases. It appears to be a private, early-revenue stage company leveraging a mix of off-the-shelf kits and custom assay development services.

OncologyNeurologyCardiovascularMetabolic DisordersPsychiatry

Technology Platform

Methylation Sensitive High Resolution Melting (MS-HRM) technology packaged into ready-to-use EpiMelt kits, including gene-specific assays, a real-time PCR master mix, and bisulfite modification kits.

Opportunities

The growing field of epigenetic research and liquid biopsy for early disease detection creates strong demand for accessible, sensitive DNA methylation analysis tools.
The company's focus on challenging sample types like FFPE and liquid biopsies aligns with key trends in oncology and personalized medicine.

Risk Factors

Faces competition from both established reagent giants and newer, high-throughput sequencing-based epigenetic platforms.
As a small, private company, scaling global distribution and marketing is a significant challenge, and demand is tied to fluctuations in research funding.

Competitive Landscape

MethylDetect competes in the niche market of DNA methylation analysis reagents against larger life science tools companies (e.g., Qiagen, Thermo Fisher) that offer alternative technologies like pyrosequencing kits, as well as against service providers and the trend towards broader, NGS-based epigenetic profiling.